ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.068,21
0,26%
S&P 500
5.445,39
0,25%
Dow Jones
38.625,82
0,10%
Euro vs US Dollar
1,07222
0,19%
Bitcoin
65.457,05
-1,77%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. NeuBase Therapeutics Inc (NBSE)

  7. NeuBase Therapeutics Inc (NBSE) News

NBSE

NeuBase Therapeutics (NBSE)

NeuBase Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NBSE
DatumZeitQuelleÜberschriftSymbolFirma
03/06/202422h08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NBSENeuBase Therapeutics Inc
31/05/202422h29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
22/05/202422h59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
16/05/202416h07Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:NBSENeuBase Therapeutics Inc
13/05/202422h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
06/05/202413h30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NBSENeuBase Therapeutics Inc
05/04/202422h05GlobeNewswire Inc.NeuBase Therapeutics Announces Receipt of Notice from NasdaqNASDAQ:NBSENeuBase Therapeutics Inc
07/03/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
23/02/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
26/01/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
17/01/202412h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
28/12/202313h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
28/12/202312h15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NBSENeuBase Therapeutics Inc
22/12/202312h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
27/11/202315h00GlobeNewswire Inc.Psychemedics Corporation Appoints Daniella Mehalik as VP - FinanceNASDAQ:NBSENeuBase Therapeutics Inc
09/11/202322h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NBSENeuBase Therapeutics Inc
06/11/202323h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
06/11/202323h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
20/10/202313h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
18/10/202314h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
29/09/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
21/09/202302h42Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:NBSENeuBase Therapeutics Inc
20/09/202323h28Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NBSENeuBase Therapeutics Inc
18/09/202322h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBSENeuBase Therapeutics Inc
18/09/202322h20Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NBSENeuBase Therapeutics Inc
18/09/202322h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
14/09/202312h03Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NBSENeuBase Therapeutics Inc
12/09/202323h20Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:NBSENeuBase Therapeutics Inc
11/09/202323h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBSENeuBase Therapeutics Inc
08/09/202313h00GlobeNewswire Inc.NeuBase Therapeutics Issues Statement Regarding Filing By ShareholderNASDAQ:NBSENeuBase Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NBSE

Kürzlich von Ihnen besucht

DBI
MDAX
MDAX
NYSE
DIS
Walt Disney
NASDAQ
MSFT
Microsoft
USOTC
BNPQY
BNP Paribas (QX)
AMEX
SPY
SPDR S&P 500
CCOM
US30
US 30
NYSE
XOM
Exxon Mobil
NASDAQ
NVDA
NVIDIA
COIN
SOLUSD
Solana
AMEX
XLF
Financial Select Sector
NYSE
KO
Coca Cola
NYSE
JPM
JP Morgan Chase
NASDAQ
AAPL
Apple
DBI
TDXP
Tec DAX
FX
EURGBP
Euro vs Sterling
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten